Lon­za of­floads spe­cial­ty in­gre­di­ents unit in $4.7B sale to Bain Cap­i­tal, Cin­ven in con­sol­i­da­tion around bio­phar­ma

With the bio­phar­ma CD­MO mar­ket on a years­long up­swing, gi­ant Lon­za has looked to re­work the game plan to keep its gold­en goose pro­duc­tive. Af­ter tin­ker­ing with its cap­sule of­fer­ings, the Swiss man­u­fac­tur­er will now of­fload an in­gre­di­ents unit that was once one of its busi­ness pil­lars.

Lon­za will sell its spe­cial­ty in­gre­di­ents busi­ness to Bain Cap­i­tal and UK pri­vate eq­ui­ty firm Cin­ven for $4.67 bil­lion as the con­tract man­u­fac­tur­er con­tin­ues to con­sol­i­date its busi­ness around bio­phar­ma work and cap­sules, the com­pa­ny said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER